HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: For example, vorinostat targets class I, II, and IV HDACs and was approved for the treatment of cutaneous T-cell lymphoma as monotherapy and also in combination with other HDAC inhibitors such as romidepsin and belinostat [74,75,76].